drugset / Trial / NCT00833664
Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
The Purpose of this study os to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and female adult subjects.
Timeline
- Start
- 2002-01
- Primary completion
- 2002-01
- Completion
- 2002-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Terbinafine | Small molecule | 250 mg | — |
Indications
No indication recorded.